Montag, 16. Januar 2017


  • Pressemitteilung BoxID 133223

Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution (OTCBB: NPHC)

(lifePR) (Boca Raton FL, ) Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC (www.nyloxin.com) will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx.

"Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm (www.receptopharm.com). "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.

Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.

"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma (www.nutrapharma.com). "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.

Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

http://www.nyloxin.com
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com

Undiscovered Equities

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Diese Pressemitteilungen könnten Sie auch interessieren

FitLine spielt weltweit auf höchstem Niveau

, Familie & Kind, PM-International AG

Handball-Weltmeister Christian Schwarzer moderierte gemeinsam mit dem Sportdirektor der PM-International AG, Torsten Weber, die Sport-Talk Runde...

Paradigmenwechsel beim Kindschaftsrecht nach Trennung und Scheidung: Wechselmodell eine gesellschaftliche Notwendigkeit

, Familie & Kind, Interessenverband Unterhalt und Familienrecht ISUV / VDU e. V.

Nach Auffassung des Interessenverbandes Unterhalt und Familienrecht (ISUV) ist ein Paradigmenwechsel im Kindschaftsrecht notwendig. Auf Grund...

Ergänzendes Hilfesystem: Opfer sexueller Gewalt können weiter Hilfe beantragen

, Familie & Kind, Bundesministerium für Familie, Senioren, Frauen und Jugend

Wer als Kind oder Jugendlicher im institutionellen Bereich sexuell missbraucht wurde, kann weiterhin Leistungen aus dem Ergänzenden Hilfesystem...

Disclaimer